SCHEDULE: Armistice Capital Discloses 9.38% Stake in Sangamo Therapeutics

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 9.38% of Sangamo Therapeutics, Inc.'s common stock, filing as a Schedule 13G.

Summary

• Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, reporting beneficial ownership of 38,860,819 shares of Sangamo Therapeutics, Inc. common stock.
• This holding represents 9.38% of the class of securities.
• The filing indicates that Armistice Capital, LLC is the investment manager for Armistice Capital Master Fund Ltd., the direct holder of the shares.
• Steven Boyd, as the managing member of Armistice Capital, LLC, may be deemed to beneficially own these shares.
• The filing is an amendment, indicating a change or update to a previous filing.
• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, indicating a significant but passive stake in Sangamo Therapeutics, Inc. without immediate intentions to influence control.

Positives

• Significant passive investment by Armistice Capital, LLC and Steven Boyd, indicating confidence in Sangamo Therapeutics' long-term prospects.
• The 9.38% stake suggests a substantial commitment to the company.
• The filing confirms the shares are held in the ordinary course of business, implying a stable, long-term investment strategy.

Negatives

• The filing does not provide specific details on the acquisition date or cost basis of the shares.
• The Master Fund disclaims beneficial ownership due to the investment management agreement, which could imply a complex ownership structure.

Risks

• Potential for future changes in beneficial ownership, which could impact share price volatility.
• The passive nature of the investment means there's no immediate indication of strategic initiatives or governance changes being pushed by the reporting persons.

Future Outlook

The filing does not contain forward-looking statements or specific guidance regarding future performance. It primarily reports on current beneficial ownership.

Management Comments

• Armistice Capital, LLC exercises voting and investment power over the securities held by the Master Fund.
• Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities.
• The Master Fund disclaims beneficial ownership of the securities held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.
• The securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that significant stake disclosures via Schedule 13G filings are common in the biotechnology and pharmaceutical sectors, often indicating institutional interest or activist positioning. Sangamo Therapeutics operates in the gene therapy space, a field attracting substantial investment and subject to evolving regulatory and scientific landscapes.

Related Party Transactions

• Armistice Capital, LLC acts as the investment manager for Armistice Capital Master Fund Ltd.
• Steven Boyd is the managing member of Armistice Capital, LLC.

Stakeholder Impact

• Shareholders may view the significant stake as a positive sign of institutional confidence, potentially leading to increased investor interest.
• The passive nature of the filing suggests no immediate impact on corporate control or strategic direction from Armistice Capital.

Next Steps

• Continued monitoring of Armistice Capital's ownership and any potential future amendments to the Schedule 13G.
• Observation of Sangamo Therapeutics' strategic developments and financial performance.

Key Dates

Recommendation

The filing indicates a substantial passive investment, which is a neutral event. While it shows confidence from Armistice Capital, there's no indication of an immediate catalyst for significant price movement or a change in control. Therefore, a 'hold' recommendation is appropriate pending further developments.

Keywords

Sangamo Therapeutics, Armistice Capital, Schedule 13G, Beneficial Ownership, Investment Management, Common Stock, SEC Filing, Steven Boyd